Exhibit 99.1
Contacts:
Andrew Graham
Director of Finance
Trimeris, Inc.
(919) 419-6050
Trimeris Reports Second Quarter 2007 FUZEON Sales Results
- Global sales in the second quarter grew 8 percent over 2006
- U.S/Canada sales in the second quarter grew 6 percent over 2006
- Ex U.S/Canada sales in the second quarter grew 11 percent over 2006
MORRISVILLE, N.C. - July 18, 2007 - Trimeris, Inc. (Nasdaq: TRMS) today announced worldwide net sales of FUZEON for the second quarter of 2007 were $62.0 million, an increase of 8 percent from $57.2 million in the second quarter of 2006. Net sales of FUZEON in the U.S. and Canada for the second quarter of 2007 were $32.9 million, up 6 percent from $31.1 million in the second quarter of 2006. Net sales of FUZEON outside the U.S. and Canada for the second quarter of 2007 were $29.2 million, an increase of 11 percent from $26.2 million in the second quarter of 2006. All sales of FUZEON are recorded by F. Hoffmann-La Roche Ltd, ("Roche"), Trimeris' collaborative partner.
Net sales of FUZEON for the first half of 2007 were $126.3 million, an increase of 12 percent from $112.7 million in the first half of 2006. Net sales of FUZEON in the U.S. and Canada for the first half of 2007 were $62.2 million, up 6 percent from $58.5 million in the first half of 2006. Net sales of FUZEON outside the U.S. and Canada for the first half of 2007 were $64.1 million, an increase of 18 percent from $54.2 million in the first half of 2006.
The release of complete financial results for the second quarter of 2007 will take place in early August, 2007.
Net Fuzeon Sales
The table below presents net FUZEON sales by quarter beginning in the first quarter of 2005:
(millions)
| | 2007 |
| | Q1 | Q2 | Q3 | Q4 | Total | | 1H |
U.S/Canada Net Sales | $29.3 | $32.9 | | | $62.2 | | $62.2 |
Ex. U.S/Canada Net Sales | 35.0 | 29.2 | | | 64.1 | | 64.1 |
Global Net Sales | $64.3 | $62.0 | | | $126.3 | | $126.3 |
Brazil Purchase | $6.0 | - | | | $6.0 | | $6.0 |
| | | | | | | | |
| | 2006 |
| | Q1 | Q2 | Q3 | Q4 | Total | | 1H |
U.S/Canada Net Sales | $27.4 | $31.1 | $33.5 | $42.2 | $134.2 | | $58.5 |
Ex. U.S/Canada Net Sales | 28.0 | 26.2 | 29.5 | 31.1 | 114.8 | | 54.2 |
Global Net Sales | $55.4 | $57.2 | $63.0 | $73.3 | $249.0 | | $112.7 |
Brazil Purchase | $5.3 | - | $4.4 | $4.7 | $14.3 | | $5.3 |
| | | | | | | | |
| | 2005 |
| | Q1 | Q2 | Q3 | Q4 | Total | | 1H |
U.S/Canada Net Sales | $23.3 | $25.2 | $28.4 | $35.8 | $112.7 | | $48.5 |
Ex. U.S/Canada Net Sales | 19.1 | 28.7 | 20.5 | 27.1 | 95.5 | | 47.9 |
Global Net Sales | $42.5 | $53.9 | $48.9 | $62.9 | $208.2 | | $96.4 |
Brazil Purchase | - | $7.3 | - | $5.5 | $12.8 | | $7.3 |
| | | | | | | | |
(numbers may not add due to rounding)
About Trimeris, Inc.
Trimeris, Inc. (Nasdaq: TRMS) is a biopharmaceutical company engaged in the development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. FUZEON, approved in the U.S., Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. For more information about Trimeris, please visit the Company's website at http://www.trimeris.com.
Trimeris Safe Harbor Statement
This document and any attachments may contain forward-looking information about the Company's financial results and business prospects that involve substantial risks and uncertainties. These statements can be identified by the fact that they use words such as "expect," "project," "intend," "plan," "believe" and other words and terms of similar meaning. Among the factors that could cause actual results to differ materially are the following: there is uncertainty regarding the success of research and development activities, regulatory authorizations and product commercializations; the results of our previous clinical trials are not necessarily indicative of future clinical trials; and our drug candidates are based upon novel technology, are difficult and expensive to manufacture and may cause unexpected side effects. For a detailed description of these factors, see Trimeris' Form 10-K filed with the Securities and Exchange Commission on March 16, 2007 and its periodic reports file d with the SEC.
--end-
